Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Diagnostic Substances
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5085
IPSCIO Record ID: 27049
IPSCIO Record ID: 26501
APTIMA(R) Technology shall mean all technology reasonably necessary to make or use Licensee's APTIMA generation of amplified nucleic acid assays, including Target Capture (TC), Transcription-Mediated Amplification (TMA), Hybridization Protection Assay (HPA) and Dual Kinetic Assay (DKA) technologies, each to the extent in each case that Licensee has a right to license or sublicense.
The technology is a diagnostic technology (genetic) for the early warning of prostate cancer.
The licensor's (Quebec, Canada) urine test (PCA3) to detect the genetic marker of prostate cancer is now being developed by the licensee based in San Diego, and after more clinical trials a new version will hit the market by year end (2005).
IPSCIO Record ID: 4321
HIV Cassette Product means the Licensee product currently known as HIV 1/2 STAT PAK(TM) as described in Licensee's PMA on file with the FDA and further described in the HIV 1/2 STAT PAK(TM) package insert, Catalog #HIV 102, together with any improvements thereto.